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Aim. To assess the significance of age, gender, baseline best corrected visual acuity, baseline macula thickness, and type and size of
choroidal neovascularization in earlymorphological therapeutic response to ranibizumab treatment in patients with thewet formof
age-related macular degeneration.Methods. From 09/2008 to 06/2013 we evaluated 1153 newly diagnosed, treatment-na¨ıve patients
treated with ranibizumab. Based on the morphological findings in the macula following the initial 3 injections of ranibizumab, the
patients were divided into two groups based on active and inactive choroidal neovascularization.Results. After the initial 3 injections
of ranibizumab, we examined the sample of 841 eyes with active CNV and 312 eyes with inactive CNV. In the inactive group, we
found a statistically higher proportion of occult CNV (𝑃 < 0.001) and lower incidence of CNV greater than 5DA (𝑃 < 0.001)
compared with the active group.We found no statistically significant difference in age, gender, baseline best corrected visual acuity,
or baseline macula thickness between the inactive and active groups. Conclusion. Occult CNV and CNV smaller than 5DA are
optimistic factors for a better morphological therapeutic response at the beginning of ranibizumab treatment.
1. Introduction
Age-related macular degeneration (AMD) is subdivided into
the dry form and the wet form. According to Bressler et al.,
90% of legal blindness from AMD is caused by the wet form
[1]. The Minimally Classic/Occult Trial of the Anti-VEGF
Antibody Ranibizumab in the Treatment of Neovascular
Age-Related Macular Degeneration (MARINA) evaluated
the benefit of ranibizumab in a dose of 0.5mg per month.
At 12 months, 95% of patients had lost <15 Early Treatment
Diabetic Retinopathy Study (ETDRS) letters from baseline
and 34%of patients had a best corrected visual acuity (BCVA)
gain of ≥15 ETDRS letters [2]. The study Ranibizumab in
Patientswith Subfoveal ChoroidalNeovascularization (CNV)
Secondary to Age-Related Macular Degeneration (SUSTAIN
study) was designed to further evaluate the safety, tolerability,
and efficacy of optical coherence tomography (OCT)/BCVA-
guided, individualized, and flexible pro re nata (PRN, as
needed) dosing regimen for ranibizumab. At 12 months,
92.5% of patients had lost <15 ETDRS letters from baseline
and 19.3% of patients had a BCVA gain of ≥15 ETDRS letters
[3].
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Whether the fixed or PRN regimen was used in the
treatment of wet AMD, the therapeutic response of individual
patients was not always the same. Current observations
suggest that the factors which affect the response to the initial
treatment with ranibizumab are individual.
The aim of this study was to assess the importance of
various factors (age, gender, baseline BCVA, baseline macula
thickness, and type and size of CNV) for early morphological
therapeutic response to ranibizumab in clinical practice.
2. The Population and Methodology
The treatment of patients with wet AMD is centralized
into 9 tertiary referral centres in the Czech Republic (see
Appendix). Anonymised data on treatment efficacy and
safety have been consecutively entered into the Czech
national database AMADEuS (Age-Related Macular Degen-
eration in patients in the Czech Republic) since September
2008. The main aim of this registry is to collect basic
epidemiologic data on patients diagnosed with wet AMD
in the Czech Republic, document standard diagnostic and
therapeutic patterns, and assess treatment efficacy in standard
clinical practice. The data collection is independent of all
treatment decisions; it does not affect a patient’s access to
treatment and fully complies with all ethical as well as legal
requirements for noninterventional data collection in the
Czech Republic. All patients have given written informed
consent to the treatment, as well as data collection. The
reported investigations were in accordance with the princi-
ples of the current version of the Declaration of Helsinki.
The data are recorded from the moment of diagnosis
and start of treatment at regular 3-month intervals for half a
year. In the following period, the record is completed every 6
months. Each record presumes biomicroscopic examination
of the retina, determination of BCVA using the ETDRS chart,
and an OCT examination (OCT 3 Stratus). The first visit
involves fluorescein angiography (FA); indocyanine green
angiography (ICGA) is used only if it is necessary for deter-
mining a diagnosis. Based on the examinations, compulsory
and optional data are specified. The compulsory data always
include BCVA expressed by the number of ETDRS letters, the
central thickness of macula in 1mm of macula in 𝜇m, and
volume in 6mmofmacula inmm3.Thefirst visit also involves
recording age and gender and measuring type and size of
CNV using FA or ICGA. Patients with diagnosed wet form of
AMDwhomeet the Czech Society of Ophthalmology criteria
for initiation of treatment with the ranibizumab are entered
into the registry. Ranibizumab therapy in the Czech Republic
is indicated in patients with AMD who are older than 50
years, with predominantly classic,minimally classic, or occult
CNV in subfoveal localization, a BCVA score between 70 and
35 letters (20/40–20/200 Snellen equivalent), total macular
lesion area ≤8 disc area (DA), and submacular haemorrhage
≤25% of the total macular lesion area. Minimally classic
and occult CNV must show signs of activity in the form of
the presence of hard exudates, subretinal haemorrhages, or
decrease in BCVA within the last 3 months by ≥10 letters
of the ETDRS chart. In patients treated with ranibizumab
in a dose of 0.5mg, there are two separate phases: the
loading phase, followed by a PRN phase. In the loading
phase, patients receive 3 consecutive monthly injections of
ranibizumab (months 0–2), followed by a PRN phase when
further treatment is given between and including months 3
and 11 according to the retreatment criteria.
Retreatment with ranibizumab is performed if the pa-
tient’s BCVA worsened against BCVA recorded in the previ-
ous visit and if there is a demonstrable macular edema on
OCT examination. The PRN method of application is also
followed in the second year and all succeeding years of patient
treatment.
Our study assessed the influence of age, gender, baseline
BCVA, baseline macula thickness, and type and size of CNV
on early morphological therapeutic response to ranibizumab
in clinical practice. We studied these factors in terms of
anatomical changes in themacula after 3 consecutivemonthly
injections of ranibizumab in the loading phase (months 0–2).
The monitored factors: age, gender, baseline best corrected
visual acuity, baseline macula thickness, and type and size
of choroidal neovascularization nor any others parameters
(visual acuity, OCT) had no influence on the treatment
scheme in the loading phase.
From 01/09/2008 to 24/6/2013, 1153 newly diagnosed,
treatment-na¨ıve patients treated with ranibizumab were
entered into the registry.
Following the 3 initial injections of ranibizumab, the
patients were divided into two groups based on the mor-
phological findings in the macula: a group with active CNV
and a group with inactive CNV. In the group with active
CNV, OCT screening revealed intraretinal macular edema,
subretinal fluid accumulation, retinal pigment epithelium
(RPE) detachment, fibrovascular RPE detachment, or the
combination of all these findings. No vitreomacular traction
was revealed.
In the group with inactive CNV, OCT screening revealed
restored foveal depression and a scar at the site of CNV with
no signs of exudation was apparent. No intraretinal macular
edema, subretinal fluid accumulation, RPE detachment, or
fibrovascular RPE detachment was found.
In both groups, we assessed the following parameters:
gender and age of patients, type and size of CNV, baseline
BCVA on the ETDRS chart, and baseline macular thickness.
Standard descriptive statistics were applied in the analy-
sis: absolute and relative frequencies for categorical variables
and median supplemented with 5th–95th percentiles and
mean supplemented by 95% confidence interval for con-
tinuous variables. The statistical significance of differences
between groups was analyzed using Pearson’s chi-square
test for categorical variables and Mann-Whitney 𝑈 test for
continuous variables. 𝛼 = 0.05 was adopted as the level of
statistical significance in all analyses.
The analysis was computed using the software PASW
Statistics 19.0.1. (SPSS, Inc. 2010) and performed by the
Institute of Biostatistics and Analyses at Masaryk University,
Brno, operating independently of anyAMD treating centre in
the Czech Republic.
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3. Results
The sample included 1092 patients, 38.6% men, average age
73.3 years (SD: 8.4), and 61.4% women, average age 74.2 years
(SD: 8.6). The analysis included 1153 treated eyes; the right
eye was treated 561 times, the left eye 592 times (both eyes
were treated 61 times).
After the initial 3 injections (day 0,month 1, andmonth 2)
of ranibizumab, in month 3 we examined the sample of 1153
eyes. Of these there were 841 eyes with active CNV (the active
group) and 312 eyes with inactive CNV (the inactive group).
The sample in the active group included 37.9% ofmen and
62.1% of women. The sample in the inactive group included
41% of men and 59% of women (𝑃 = 0.338, Pearson’s chi-
square test).
The active and the inactive group included 29.3% and
27.9% of patients at the age <70 years, 43.4% and 42.9% of
patients aged 70–80 years, and 27.3% and 29.2% of patients
at the age >80 years (𝑃 = 0.237, Mann-Whitney 𝑈 tests),
respectively.
The active and the inactive group included 31% and
20.2% of patients with predominantly classic CNV, 21%
and 19.9% with minimally classic CNV, and 47.9% and
59.9% with occult CNV, respectively. The inactive group
showed statistically significantly higher presence of occult
membranes and statistically significant lower presence of
predominantly classic CNVs compared with the active group
(𝑃 < 0.001, Pearson’s chi-square test).
The active and the inactive group included 23.8% and
26.9% of patients with CNV < 2 disc areas (DA), 66.8%
and 70.2% of patients with CNV 2–5DA, 9.4% and 2.9% of
patients with CNV > 5DA, respectively. The inactive group
showed statistically significantly lower presence of CNV >
5DA compared with the active group (𝑃 < 0.001, Pearson’s
chi-square test).
The baseline BCVA in the range of 15–30 ETDRS letters
was shown in 10.2% of patients in the active group and 10.9%
of patients in the inactive group.TheBCVA in the range of 31–
60 ETDRS letters was shown in 62.5% of patients in the active
group and 55.1%of patients in the inactive group.Thebaseline
BCVAof>60 ETDRS letters was shown in 27.2% of patients in
the active group and 34%of patients in the inactive group.The
median of the baseline BCVA was 54 (5–95 percentiles: 22–
73) and 55 (5–95 percentiles: 23–75) in the active and inactive
group, respectively. We found no statistically significant
difference in the value of the baseline BCVA between the
groups (𝑃 = 0.066, Mann-Whitney 𝑈 test).
19.3% of patients in the active group and 15.6% of patients
in the inactive group had a baseline macular thickness of
<250𝜇m.The baselinemacular thickness in the range of 250–
400 𝜇mwas shown in 51.7% of patients and 58.5% of patients,
respectively, and baseline macular thickness of >400 𝜇m
was shown in 29% and 25.9% of patients, respectively. The
median of the baseline macular thickness was 330 𝜇m (5–
95 percentiles: 190–600) and 337 𝜇m (5–95 percentiles: 201–
535) in the active and inactive group, respectively. There
was no statistically significant difference in the value of the
baseline macular thickness between groups (𝑃 = 0.663,
Mann-Whitney 𝑈 test).
4. Discussion
In the literature, we found no publications describing prog-
nostic factors for early morphological therapeutic response
to treatment with ranibizumab in patients with wet AMD.
We found only articles on prognostic factors for functional
therapeutic response. Sarks, Killingsworth, and Gonzales
noted that occult CNVmay have a good functional treatment
response. Sarks et al. [4] and Killingsworth [5] demonstrated
histologically that the onset of CNV is characterized by intra-
choroidal neovascularization followed by sub-RPE fibrovas-
cular proliferation. Occult CNV which is fibrovascular tissue
in the sub-RPE space may in part represent an earlier stage
of CNV because it is in the same tissue plane. Up to 50% of
occult CNV may then progress to classic CNV. Occult CNV
as an earlier stage of the disease is assumed to be associated
with less damage to photoreceptors in macula and successful
treatment has a better prognosis [6].
In our study, we evaluated the impact of gender, age,
baseline BCVA, baseline macular thickness, and type and
size of CNV on early morphological therapeutic response
following the 3 initial injections of ranibizumab. In the
inactive group of 312 patients with complete regression of
CNV activity after the initial 3 injections of ranibizumab,
we found a statistically significantly higher proportion of
occult membranes, statistically significant lower presence of
predominantly classic CNV (𝑃 < 0.001), and statistically
significantly lower incidence of CNV > 5DA (𝑃 < 0.001)
compared with the active group. We observed that smaller
and occult CNV lesions have potentially better morpholog-
ical therapeutic response with the disappearance of the CNV
activity and resorption of the macular edema.
We found no significant impact of gender, age, value of
baseline BCVA, or baseline macular thickness on early mor-
phological therapeutic response after the initial 3 injections
of ranibizumab.
The question remains whether positive morphological
therapeutic outcomes are connected to positive functional
results. Additional studies are needed to further clarify
the relationship of morphological and functional results in
ranibizumab treated patients with wet age-related macular
degeneration.
5. Conclusion
The results showed positive early morphological therapeutic
response with restored foveal depression and no signs of
exudation onOCT in patients with higher incidence of occult
CNV, lower incidence of predominantly classic CNV, and
lower incidence of CNV > 5DA.
There was no evidence of any effect of age, gender,
baseline best corrected visual acuity, or baseline macula
thickness on the early anatomical restoration of the macula.
We believe that occult CNV and aCNV smaller than 5DA are
optimistic for better morphological therapeutic response at
the beginning of ranibizumab therapy. To determine if other
factors influence the morphological response to ranibizumab
treatment in patients with wet AMD, further clinical studies
are needed.
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Appendix
Participating AMADEUS Clinical Sites are as follows.
Department of Ophthalmology, Faculty of Medicine in
Hradec Kra´love´, Charles University in Prague and Univer-
sity Hospital in Hradec Kra´love´, Czech Republic: Associate
Professor Jan Studnicˇka MD., Ph.D., Jaroslava Dusova´ MD.,
Ivana Cermanova´, Gabriela Blazˇkova´; Department of Oph-
thalmology, First Faculty of Medicine, Charles University in
Prague and General University Hospital in Prague, Czech
Republic: Zora Dubska´, MD., Ph.D., Bohdan Kousal, MD;
Department of Ophthalmology, University Hospital, Olo-
mouc, Czech Republic: Professor Jirˇ´ı Rˇeha´k, MD., Ph.D.,
FEBO, Oldrˇich Chrapek, MD., Ph.D., Zuzana Pracharˇova´,
MD., Martin Sˇı´n, MD., Ph.D., FEBO; Department of Oph-
thalmology, First Faculty of Medicine, Charles University
in Prague and Central Military Hospital in Prague, Czech
Republic: Jan Ernest, MD., Ph.D; Department of Ophthal-
mology,UniversityHospital, Brno, CzechRepublic: Associate
Professor Petr Kola´rˇ, MD., Ph.D., Daniela Vyslouzˇilova´, MD.,
Veronika Matusˇkova´, MD; Department of Ophthalmology,
Masaryk Hospital, U´st´ı nad Labem, Czech Republic: Martin
Hovorka, MD., Martina Za´vorkova´, MD; Department of
Ophthalmology, University Hospital, Ostrava, Czech Repub-
lic: Jan Neˇmcˇansky´, MD., Pavel Sˇmehl´ık, MD; Department
of Ophthalmology, Faculty of Medicine in Plzenˇ, Charles
University in Prague and University Hospital in Plzenˇ,
Czech Republic: Dagmar Frdl´ıkova´, MD., Hana Fidranska´,
MD., Toma´sˇ Nathansky´, MD; Department of Ophthalmol-
ogy, Teaching Hospital Kra´lovske´ Vinohrady, Prague, Czech
Republic: Miroslav Veith, MD., Stanislava Pokorna´, MD.
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